Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CUMBERLAND PHARMACEUTICALS INC
Report date March 17, 2022 · Filed April 29, 2022
Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,473 |
Reported balance
After 2022-03-17 transaction · row 1
1 source rowRow 1 · 2022-03-17 · Other · Disposed 15,000 · Balance 163,473 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2022-03-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-17 · Other · Disposed 5,000 · Balance 0 F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Cearnal passed away on March 17, 2022. All unvested equity awards forfeited upon death.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.71 | $284.55 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,509 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 11, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.73 | $286.65 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,404 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 08, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.84 | $298.20 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,299 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 07, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.76 | $289.80 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,194 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 06, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.76 | $289.80 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,089 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 05, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.82 | $296.10 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,984 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 04, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.87 | $301.35 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,879 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| October 01, 2021 Filed Nov 5, 2021 21:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.69 | $282.45 |
DisclosureSEC source: 0001209191-21-063217 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,774 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.72 | $285.60 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 21 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,669 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.82 | $296.10 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 20 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,564 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 28, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.76 | $289.80 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 19 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,459 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 27, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.79 | $292.95 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 18 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,354 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 24, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.74 | $287.70 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 17 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,249 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 23, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.75 | $288.75 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 16 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,144 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 22, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.76 | $289.80 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 15 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,039 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 21, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.81 | $295.05 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,934 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 20, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.82 | $296.10 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,829 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 17, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.85 | $299.25 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,724 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 16, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.91 | $305.55 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,619 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 15, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.86 | $300.30 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,514 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 14, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.02 | $317.10 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,409 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 13, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.96 | $310.80 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,304 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 10, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.78 | $291.90 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,199 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 09, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.77 | $290.85 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,094 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 08, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.89 | $303.45 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,989 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 07, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.79 | $292.95 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,884 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 03, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.85 | $299.25 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,779 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 02, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.88 | $302.40 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,674 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| September 01, 2021 Filed Oct 1, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.88 | $302.40 |
DisclosureSEC source: 0001209191-21-058506 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,569 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 31, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.93 | $307.65 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 21 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,464 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 30, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.88 | $302.40 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 20 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,359 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 27, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.84 | $298.20 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 19 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,254 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 26, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.82 | $296.10 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 18 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,149 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 25, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.79 | $292.95 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 17 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,044 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 24, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.89 | $303.45 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 16 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,939 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 23, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.87 | $301.35 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 15 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,834 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 20, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.96 | $310.80 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 14 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,729 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 19, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.02 | $317.10 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 13 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,624 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 18, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.97 | $311.85 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 12 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,519 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 17, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.05 | $320.25 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 11 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,414 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 16, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.92 | $306.60 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 10 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,309 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 13, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.92 | $306.60 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 9 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,204 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 11, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.98 | $312.90 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 8 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,099 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 10, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.96 | $310.80 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 7 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,994 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 09, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $2.93 | $307.65 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 6 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,889 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 06, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.01 | $316.05 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 5 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,784 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 05, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.11 | $326.55 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 4 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,679 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 04, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.18 | $333.90 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 3 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,574 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 03, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.17 | $332.85 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 2 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,469 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
| August 02, 2021 Filed Sep 10, 2021 21:03 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 105 | $3.34 | $350.70 |
DisclosureSEC source: 0001209191-21-055478 · doc4.xml · nonDerivative · entry 1 Cearnal Martin E · CIK 0001408500 · Director · Sr VP/Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,364 F1 · shares: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.